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Abstract
Background: Many (artificial) bone substitute materials are currently available for use in orthopaedic trauma
surgery. Objective data on their biological and biomechanical characteristics, which determine their clinical
application, is mostly lacking. The aim of this study was to investigate structural and in vitro mechanical properties
of nine bone substitute cements registered for use in orthopaedic trauma surgery in the Netherlands.
Methods: Seven calcium phosphate cements (BoneSource®, Calcibon®, ChronOS®, Eurobone®, HydroSet™, Norian
SRS®, and Ostim®), one calcium sulphate cement (MIIG® X3), and one bioactive glass cement (Cortoss®) were
tested. Structural characteristics were measured by micro-CT scanning. Compression strength and stiffness were
determined following unconfined compression tests.
Results: Each bone substitute had unique characteristics. Mean total porosity ranged from 53% (Ostim®) to 0.5%
(Norian SRS®). Mean pore size exceeded 100 μm only in Eurobone® and Cortoss® (162.2 ± 107.1 μm and 148.4 ±
70.6 μm, respectively). However, 230 μm pores were found in Calcibon®, Norian SRS®, HydroSet™, and MIIG® X3.
Connectivity density ranged from 27/cm3 for HydroSet™ to 0.03/cm3 for Calcibon®. The ultimate compression
strength was highest in Cortoss® (47.32 MPa) and lowest in Ostim® (0.24 MPa). Young’s Modulus was highest in
Calcibon® (790 MPa) and lowest in Ostim® (6 MPa).
Conclusions: The bone substitutes tested display a wide range in structural properties and compression strength,
indicating that they will be suitable for different clinical indications. The data outlined here will help surgeons to
select the most suitable products currently available for specific clinical indications.
Background
Treatment of bone defects is a continuous challenge in
skeletal trauma and orthopaedic trauma surgery. Bone
graft represents the second most common transplanted
tissue, with blood being number one [1]. Worldwide,
more than 2.2 million bone grafting procedures are per-
formed annually for the repair of bone defects in ortho-
paedic traumatology, neurosurgery, and dentistry [2-4].
Approximately 10% of all skeletal reconstructive surgical
interventions require bone grafting [4]. Large defects
resulting from, among others, trauma, infection, or
tumor resection often do not heal spontaneously, and
require surgical intervention. In addition, the treatment
of posttraumatic skeletal complications such as delayed
unions, nonunions, or malunions frequently require
bone grafting. Variations in size or location of the
defect, but also patient related factors such as age and
disease status determine the therapeutic approach.
Herein, bone grafts provide support, fill voids, and
enhance the biological repair of the defect.
Autogenous bone, either cortical or cancellous, har-
vested from the patient’s iliac crest is considered the
gold standard graft. Autogenous bone is an excellent
grafting material, since it provides three of the four criti-
cal elements for bone repair; an osteoconductive matrix
that provides a scaffold for bone ingrowth, growth fac-
tors that stimulate osteoinduction, and living bone cells
that offer osteogenesis [5]. However, as the cells do not
necessarily survive transplantation, the clinical benefit is
not guaranteed per se [6]. Several limitations have been
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noted, including a limited amount or inappropriate
shape of the graft [1]. Also, the harvesting of autogenous
bone tissue lengthens the surgical procedure, and is
associated with an 8-39% risk of complications that
include infection, blood loss, haematoma, nerve and ure-
thral injury, fracture, pelvic instability, cosmetic disad-
vantages, postoperative pain, and morbidity and chronic
pain at the donor site [1,7-14]. Finally, the use of auto-
grafts is not recommended in elderly or pediatric
patients or in patients with a malignancy or infectious
disease.
Alternative bone grafts like iso-, allo-, and xeno-trans-
plants have been applied, but due to (major) disadvan-
tages their use is discouraged (for review, see [1,8]).
The first use of plaster of paris (gypsum) as an artifical
bone substitute was reported on in 1892 [15]. Technolo-
gical evolution and a better understanding of bone-heal-
ing biology have led to the development of alternative
(synthetic) bone substitutes. In the eighties, calcium
phosphate salts such as tricalciumphosphate (TCP) and
hydroxyapatite (HA) were introduced for clinical use
[16]. Although they do not exist naturally, TCP and HA
have been shown to induce a biologic response similar
to that of bone [1]. Other groups of compounds avail-
able are calcium sulphate (gypsum), type I collagen and
non-biologic substrates like degradable polymers and
bioactive glass [1,17,18]. Over 20 bone substitute pro-
ducts are registered at present for use in orthopaedic
trauma surgery in the Netherlands [19]. They differ in
composition, characteristics, appearances, and delivery
forms (e.g., pastes, solid matrices, or granules).
Availability of an increasing number of products may
seem attractive; however, without sufficient knowledge
on their properties and behavior in vivo it will become
more and more complicated to select the product that
mimics the bone to be replaced the best. Determining
which product to use is based upon many factors
including the size and location of the defect as well as
the handling properties and ability to deliver the mate-
rial to the surgical site. The structure and biomechanical
characteristics of the products are critical to their suc-
cess. For the majority of products, these data are mostly
lacking. The aim of this study was to investigate the in
vitro porosity, structure characteristics, and compression
strength and stiffness of bone substitutes that were
registered for use in orthopaedic trauma surgery in the
Netherlands and were available as (injectable) paste.
Standardized tests were performed.
Methods
Sample preparation
Nine bone substitutes that were available as (injectable)
paste were selected for biomechanical testing; seven cal-
cium phosphate cements, one calcium sulphate and one
bioactive glass (Table 1). The products were stored at
room temperature until use. Ten to 12 cylindrical test
samples were prepared per product using a custom-
made Teflon mould (Dept. Experimental Medical Instru-
mentation, Erasmus MC, Rotterdam, the Netherlands;
Figure 1). Samples had a length of 8 mm and a diameter
of 4 mm. This 2:1 ratio was the optimal ratio according
Hing et al [20]. Samples were allowed to harden for
20 minutes at room temperature, after which micro-CT
scanning was performed. Sample density was calculated
from the length, diameter and weight. Subsequently,
samples were kept at 37°C for 3 days in sterile water to
allow for maximal hardening, upon which a compres-
sion test was performed.
Micro-CT scanning
Architecture was determined using a micro-CT (Skyscan
1076, Kontich, Belgium). The micro-CT was tuned at 70
kV and 140 μA, with a resolution of 9 μm. This setup
was verified by scanning a Vitoss® test sample with a
known porosity between 88 and 92% [21], which was
indeed within this range (data not shown). CT shadow
projection images were converted into a three dimen-
sional reconstruction of cross-sectional images in bit-
map files using the volumetric reconstruction software
(Nrecon software, Skyscan, Belgium). Total, closed and
open porosity, connectivity density, structure model
Table 1 Bone substitutes tested for their biomechanical
characteristics
Main ingredient Product name Producer
Calcium phosphate BoneSource® Stryker Nederland B.V.
Calcibon® Biomet Europe
ChronOS® Inject Synthes, Inc
Eurobone® Surgical concepts
HydroSet™ Stryker Nederland B.V.
Norian SRS® Synthes, Inc
Ostim® Hereaus
Calcium sulphate MIIG® X3 Wright Medical, Inc
Bioactive glass Cortoss® Orthovita, Inc
Figure 1 Production of test samples Test samples with a height
of 8 mm and a diameter of 4 mm were made using a custom-
made Teflon mold (panel A). Panel B shows examples of Calcibon®
test samples.
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index (SMI) and pore size were calculated from these
3D reconstruction using the CTAn software (SkyScan,
Kontich, Belgium). Total porosity was defined as the
volume of all open plus closed pores as a percent of the
total Volume Of Interest (VOI) volume. Closed porosity
represents the volume of the closed pores as a percent
of the total of solid plus closed pore volume within the
VOI. Open porosity is defined as the volume of open
pores as a percent of the total VOI volume. Connectivity
density is the number of redundant connections
between trabecular structures per unit volume. The SMI
indicates the relative prevalence of rods and plates in a
3D structure. Pore size was defined as the average thick-
ness of the pores, similar to the definition of trabecular
spacing and thickness [22].
Biomechanical testing
The compression strength was determined using uncon-
fined compression tests. Upon five consecutive non-
destructive preconditioning cycles, samples were com-
pressed at a velocity of 0.5 mm/min to fracture using a
standard compression-testing device (Lloyd Instruments,
Fareham, UK). The resulting Extension-force curves
were converted to Strain-stress curves using formulas I
and II:
(I) Strain (mm/mm) = Extension/Lo
(II) Stress (MPa) = Force/Ao
Herein, Lo is the original length of the sample and Ao
is area of the sample. The ultimate strength (MPa) was
determined as the maximum force applied per square
mm recorded during the experiment. Stiffness (Young’s
modulus; MPa) was determined as the slope of the lin-
ear fit detected during the test.
Data analyses
Statistical analyses were performed using the Statistical
Package for the Social Sciences (SPSS) version 16.0
(SPSS, Chicago, IL, USA). First, a One-Way Analysis of
Variance (ANOVA) was performed to test the hypoth-
esis that the mean value for a given parameter was
equal for all products. Subsequently, post hoc pairwise
multiple comparisons were performed using the Stu-
dent’s T-test, with Bonferroni correction for multiple
testing. P-values < 0.05 were considered statistically
significant.
Results
Sample characteristics
The average length and diameter were measured in
order to check whether the test samples size was as
intended. Results are shown in Table 2. The length ran-
ged from 7.694 ± 0.104 mm (mean ± SD) for Ostim® to
8.365 ± 0.085 mm for Eurobone®. The diameter ranged
from 3.650 ± 0.103 mm for Ostim® to 3.992 ± 0.047 for
Calcibon®. Both the length and diameter of Ostim®
were statistically significantly less than the other pro-
ducts, implying that the Ostim® samples had slightly
shrunken (p < 0.001, Mann-Whitney U-test).
The average weight of the test samples varied twofold.
The lowest recorded mean weight was 103.3 ± 7.2 mg
for Ostim®, whereas MIIG® X3 had a weight of 199.0 ±
5.4 mg (Table 2).
The density of all test samples was calculated from the
length, diameter and weight (Figure 2). The CaSO4
MIIG® X3 had the highest density (1.92 ± 0.08 mg/
mm3), followed by the bioactive glass Cortoss® and the
CaPO4 Eurobone
®, which both had an average density
of 1.79 mg/mm3. The density of the other CaPO4 pro-
ducts ranged from 1.78 ± 0.07 mg/mm3 (BoneSource®)
to1.29 ± 0.09 mg/mm3 (Ostim®). The density of MIIG®
X3 was significantly higher than all other products,
whereas the density of Ostim® was significantly lower.
Porosity and pore size
In order to gain insight into the porous structure of the
bone substitute materials, the porosity and pore sizes
were calculated from micro-CT images. Ostim® was the
only product that had a clear porous structure. The
total porosity (52.66 ± 10.14%) was significantly higher
than the porosity of all other products (Figure 3A). The
porosity of the other products diminished from 6.93 ±
1.32% (ChronOS®) to 0.48 ± 0.15% for Norian SRS®. As
total porosity is dictated by open as well as closed
pores, the open porosity and closed porosity were also
determined. Open porosity was evident for Ostim®
(50.52 ± 4.49%; Figure 3B), and diminished from 2.86 ±
0.92% (ChronOS®) to 0.22 ± 0.75% for Calcibon®.
Closed porosity exceeded was highest for ChronOS®
Table 2 Average length, diameter and weight of the test
samples
N Length (mm) Diameter (mm) Weight (mg)
BoneSource® 10 8.225 ± 0.052 3.980 ± 0.035 181.8 ± 6.1
Calcibon® 12 8.271 ± 0.045 3.992 ± 0.047 179.5 ± 6.1
ChronOS® 10 8.265 ± 0.147 3.970 ± 0.059 174.5 ± 9.3
Eurobone® 10 8.365 ± 0.085 3.985 ± 0.053 186.5 ± 5.7
HydroSet™ 10 8.325 ± 0.079 3.970 ± 0.042 179.8 ± 13.0
Norian SRS® 10 8.180 ± 0.079 3.915 ± 0.034 171.9 ± 2.6
Ostim® 9* 7.694 ± 0.104 3.650 ± 0.103 103.3 ± 7.2
MIIG® X3 10 8.345 ± 0.064 3.985 ± 0.053 199.0 ± 5.4
Cortoss® 10 7.979 ± 0.103 3.854 ± 0.062 166.4 ± 4.6
Samples of bone substitute products were prepared using a custom-made
Teflon mold as indicated in the Materials and Methods. The length and
diameter were measured in order to confirm the intended size (8 mm length
and 4 mm diameter). Data are presented as mean ± SD.
*, one test sample was discarded due to the presence of air bubbles.
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(3.59 ± 0.41%) and HydroSet™ (2.66 ± 0.49%), and low-
est for Ostim® (0.43 ± 0.32%), Norian SRS® (0.33 ±
0.13%), and MIIG® X3 (0.29 ± 0.07%; Figure 3C).
The porous structure of the bone substitute materials
is determined by their porosity and pore size. Only two
products had a mean pore size that exceeded 100 μm, i.
e., 162.2 ± 107.1 μm for Eurobone® and 148.4 ± 70.6
μm for Cortoss® (Figure 4). Pore sizes of Norian SRS®
(47.2 ± 21.9 μm), Calcibon® (41.6 ± 22.0 μm) and Bone-
Source® (33.4 ± 6.2 μm) were below 50 μm.
For each product the range in pore sizes is shown in
Figures 5. Of all products, BoneSource® had the smallest
pores. Over 95% of pores were smaller than 60 μm, of
which approximately half were < 26.7 μm. No pores >
100 μm were found. This was also seen in Ostim®, of
which 95% of pores were smaller than 85 μm. Calcibon®,
Norian SRS® and HydroSet™ incidentally showed pores
up to 230 μm, however 95% were smaller than 125 μm.
Of the CaPO4 products, ChronOS® and Eurobone® were
the only two that contained pores up to 500 μm, with
95% of pores being smaller than 250 μm and 330 μm,
respectively. The distribution of pore sizes of the CaSO4
MIIG® X3 appeared similar as that of Norian SRS® and,
to a lesser extent, Calcibon®. However, with a maximum
pore size of 250 μm and 90% of pores being < 190 μm,
pores of MIIG® X3 were relatively larger. The pore size
frequency of Cortoss® deviated from that of the other
products tested, as a large range of pore sizes (25 to 300
μm) were approximately equally present. In this bioactive
glass 95% of pores had sizes up to 390 μm, although
pores of 500 μm were also found. Combining the data of
total porosity and average pore size implied that bone
substitute materials provide a wide range of products.
Some had a high porosity with small pores (e.g., Ostim®),
and at the other side of the spectrum products had a low
porosity with large pores (e.g., Eurobone®).
Figure 2 Densities of bone substitutes Densities of individual test samples were calculated from their length, diameter and weight. Each dot
represents an individual test sample, and lines indicate the average value. The table below the figure provides an overview of the statistical
analysis of pairwise comparisons (Student’s T-test with Bonferroni correction). *, p < 0.05; **, p < 0.01; ***, p < 0.005; ns, not statistically
significantly different. Grey boxes represent the self-self combinations, which could not be tested.
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Figure 3 Porosity of bone substitutes Porosity of individual test samples was determined upon Micro-CT-scanning as described in the
Materials and Methods. The total porosity (A), open porosity (B) and closed porosity (C) were determined. Each dot represents an individual test
sample, and lines indicate the average value. The table below the figure shows the outcome of the pairwise comparisons (Student’s T-test with
Bonferroni correction). *, p < 0.05; **, p < 0.01; ***, p < 0.005; ns, not statistically significantly different. Grey boxes represent the self-self
combinations, which could not be tested.
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Connectivity density and structure model index
In order to further characterize the architecture of the
bone substitutes, their connectivity density and structure
model index were determined. The connectivity density
was >25/cm3 for HydroSet™ (27.17 ± 6.22/cm3), and
between 5 and 10 for Norian SRS®, MIIG® X3, and
Ostim® (8.77 ± 2.81, 5.87 ± 2.32, and 5.80 ± 0.84/cm3,
respectively; Figure 6).
Ostim® was the only product with a positive structure
model index (SMI) (0.125 ± 1.165; Figure 7). For the
other products, the SMI declined from -37.715 ± 7.280
for ChronOS® and -67.752 ± 8.913 for HydroSet™ to
-123.717 ± 38.232 for Cortoss®.
Compression strength and Young’s modulus
The compression strength of all products was deter-
mined using unconfined compression tests. Cortoss®
had the highest ultimate compression strength (47.32 ±
20.34 MPa; see Figure 8). This was statistically
significantly higher than the strength of all other pro-
ducts. Next in order of diminishing strength were Calci-
bon® and Norian SRS® (33.95 ± 6.75 and 25.64 ± 7.37
MPa, respectively), which was statistically significantly
higher than most other products. ChronOS® and
Ostim® had poor compression strengths (0.81 ± 0.32
and 0.24 ± 0.05 MPa, respectively).
Calcibon® had the highest Young’s modulus (790 ± 132
MPa; Figure 9), followed by Norian SRS® and MIIG® X3
(674 ± 146 MPa and 665 ± 154 MPa, respectively). The
Young’s modulus of these three products was statistically
significantly higher than that of the other products.
ChronOS® and Ostim® had a very low Young’s modulus
(54 ± 20 MPa and 6 ± 3 MPa, respectively), which was
statistically significantly lower than all other products.
Discussion
Osteoconductive porous biomaterials provide a scaffold
for the ingrowth of bone. With respect to pore size,
Figure 4 Average pore sizes of bone substitutes Average pore sizes of individual test samples were determined upon Micro-CT-scanning as
described in the Materials and Methods. Each dot represents an individual test sample, and lines indicate the average value. The table below
the figure shows the outcome of the pairwise comparisons (Student’s T-test with Bonferroni correction). *, p < 0.05; **, p < 0.01; ***, p < 0.005;
ns, not statistically significantly different. Grey boxes represent the self-self combinations, which could not be tested.
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microporosity (i.e., pores with a size < 5 μm) is consid-
ered important for the bioresorbability of the material
[23], whereas macroporosity (i.e., pores > 100 μm) plays
an important role in the osteoconductivity. A large
macroporosity (i.e., 400-600 μm) facilitates infiltration
by fibrovascular tissue and revascularization, thereby
allowing for bone reconstruction. Investigations of bone
ingrowth into porous materials with varying pore size
have led to the consensus that the optimal pore radius
for bone ingrowth is >50 μm and perhaps as large as
150 μm [24-27]. Of the bone substitute materials tested,
Eurobone®, Cortoss®, and ChronOS® could be consid-
ered as truly osteoconductive in terms of pore size, as
they contain a considerable number of pores with sizes
of up to 500 μm. For ChronOS® the presence of pore
sizes between 100 and 400 μm have been shown before
[28,29]. Pore sizes between 100-250 μm are only mar-
ginally present in Calcibon®, HydroSet™, MIIG® X3,
and Norian SRS®. BoneSource® and Ostim® do not
contain pores with a size of at least 100 μm, so based
upon this in vitro measurement, these might not be
considered as highly osteoconductive based upon pore
size alone. This is in agreement with literature data
available for BoneSource® (2-50 μm) [30] and Calcibon®
(<1 μm) [31].
The invasion by host tissue is mostly facilitated by a
larger porosity. Of the products tested, Ostim® is the
only product with a high mean total porosity of approxi-
mately 53%. Porosity of all other products is below 7%,
with Norian SRS® being the densest (0.48% mean total
porosity). The total porosity as found for Cortoss® (1.48
± 0.94%) is in line with the 1% mentioned by the sup-
plier. It is unclear why porosities of some other products
were lower than previously published data, indicating a
porosity of 60-75%) for ChronOS® [28,29], 46% for
BoneSource® [32,33], and 30-40% for Calcibon® [31,34].
This difference is unlikely to be due to an inadequate
test design, since the porosity of 88-92% as found for
the Vitoss® test sample was exactly as previously shown
[21]. As pores with a diameter below 9 μm could not be
detected due to resolution restrictions of the CT scan-
ner used in the present study, it cannot be ruled out
that porosity and pore sizes are (slightly) under-esti-
mated or overestimated, respectively. However, this
Figure 5 Distribution of pore sizes of bone substitutes The frequency of pore sizes varying from 10 to 500 μm are shown. Bars indicate the
mean ± SD of the individual test samples (N = 9 to 12 per product). For each product, a typical example is given in the upper right corner of
the panel.
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unlikely explains differences between our data and lit-
erature data.
Adequate pore volume alone is not sufficient for
achieving osteoconduction. Pore connectivity may deter-
mine the effectiveness of porosity [20,24,35-42]. In gen-
eral, biomaterials with interconnected pores are
considered to be superior to biomaterials containing
closed pores, as interconnecting fenestrations provide
the space for vascular tissue required for continued
ingrowth of mineralized bone [27,35,36]. White & Shors
indicated that such pore interconnections must be larger
than 100 μm [37]. Of the products tested in this study,
HydroSet™, Norian SRS®, MIIG® X3, and Ostim® had
more than five interconnected pores per cm3. Connec-
tivity density of the other products was 0.23/cm3 or less.
A negative correlation was found between pore size and
connectivity density (Pearson correlation, rp = -0.21, p =
0.043), indicating that products with a lower pore size
had a higher representation of interconnected pores.
The structure model index (SMI) indicates the relative
prevalence of rods and plates in a 3D structure. SMI
involves a measurement of surface convexity. Concave
surfaces of enclosed cavities represent negative convexity
to the SMI parameter. SMI values of ideal plates, cylin-
ders and spheres are 0, 3, and 4, respectively. With a
mean SMI value <0.2 Ostim® appears to be mainly
composed of plates. It is known that products with a
total porosity below 50% often have a negative SMI. In
this study, that was the case for eight out of nine pro-
ducts. Overall, SMI is positively correlated with total
porosity, open porosity, and closed porosity (rp = 0.672,
0.645 and 0.358, respectively; p < 0.001), and negatively
with compression strength and Young’s Modulus (rp =
-0.679 and -0.638, respectively, p < 0.001).
Figure 6 Connectivity density of bone substitutes The connectivity density of individual test samples was determined upon Micro-CT-
scanning as described in the Materials and Methods. Each dot represents an individual test sample, and lines indicate the average value. The
table below the figure shows the outcome of the pairwise comparisons (Student’s T-test with Bonferroni correction). *, p < 0.05; **, p < 0.01; ***,
p < 0.005; ns, not statistically significantly different. Grey boxes represent the self-self combinations, which could not be tested.
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Although faster ingrowth is favoured by a more por-
ous and interconnected structure, denser ceramics have
better mechanical integrity [20,24,27]. For example, an
increase of the total porous volume from 10% to 20%
can result in a four-fold decrease in mechanical strength
[27,43,44]. Of the bone substitute products tested, this
phenomenon is most pronounced for Ostim®. Ostim®
has the highest total porosity (mean ~53%), but has
poor compressive strength (mean 0.24 MPa) and
Young’s modulus (6 MPa). Calcibon® and Norian SRS®,
on the other hand, have low porosity (0.93% and 0.48%,
respectively), but display a relatively high compressive
strength (33.9 MPa and 25.6 MPa, respectively). Our
data are in line with previous measurements, which
revealed a compression strength of 6.3-34 MPa for
BoneSource® [45,46], 35-55 MPa for Calcibon® [34,47],
14-24 MPa for HydroSet™ [48], and 23-55 MPa for
Norian SRS® [49-51]. For MIIG® X3, an in vivo
compression strength of 0.6 MPa has been shown at 13
weeks follow up in a canine fracture model [52]. This is
lower than the 21.82 ± 21.93 MPa found in the current
in vitro study, and is most likely due to a high degree of
biodegradation and resorption of the MIIG® X3 graft, as
calcium sulphates are generally resorbed within 8-10
weeks. The 91-179 MPa as published for Cortoss® [53]
is higher than we found. This may be due to the larger
size of the test samples (i.e., 8 × 7.5 × 100 mm) in the
study by Boyd et al. [53]. As size and shape of the tested
samples as well as the test setup itself may influence the
outcome of the compression test, our data may allow
for a more objective comparison of strengths between
the products.
Overall, compression strength was negatively corre-
lated with total porosity (rp = -0.424, p < 0.001), open
porosity (rp = -0.399, p < 0.001), closed porosity (rp =
-0.412, p < 0.001), and connectivity density (rp = -0.220,
Figure 7 Structure model index of bone substitutes The structure model index of individual test samples was determined upon Micro-CT-
scanning as described in the Materials and Methods. Each dot represents an individual test sample, and lines indicate the average value. The
table below the figure shows the outcome of the pairwise comparisons (Student’s T-test with Bonferroni correction). *, p < 0.05; **, p < 0.01; ***,
p < 0.005; ns, not statistically significantly different. Grey boxes represent the self-self combinations, which could not be tested.
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p = 0.034) (data not shown). Likewise, Young’s modulus
was negatively correlated with total, open and closed
porosity (rp = -0.573, -0.539 and -0.491, respectively, p <
0.001). As opposed to porosity, pore size was unrelated
to the compression strength (rp = 0.113, p = 0.281) or
the Young’s modulus (rp = -0.204, p = 0.050; data not
shown).
The compounds tested in the current study represent
the major classes of artificial bone grafts, i.e., calcium
phosphates, calcium sulphate, and bioactive glass.
Although selected based upon their availability in the
Netherlands, their wide availability makes the data pre-
sented in this study generally relevant to most countries.
Synthetic calcium phosphate cements can be moulded
to irregularly shaped defects, or even injected via syringe
before they harden in situ. The two main forms of cal-
cium phosphates currently used are beta-tricalcium
phosphate (b-TCP) and hydroxyapatite (HA), which can
be used separately or combined in composite cements.
Due to a general lack of macroporosity calcium phos-
phate cement degrades layer by layer from the outside
to the inside. HA-cements tested include such as
Ostim® and HydroSet® have a limited resorption rate.
They are characterized by a high porosity, but a rela-
tively low compressive strength. Clinical indications for
Ostim® include fractures of the tibia plateau [54,55], cal-
caneus [54], and distal radius [54,56,57]. There are cur-
rently no publications on clinical use of HydroSet™.
b-TCP has a compressive strength similar to that of
cancellous bone [58], which may allow earlier weight
bearing. However, it has a relatively high resorption
rate. The b-TCPs ChronOs™ is mostly used in vertebral
augmentation [59].
Combining HA and b-TCP improves the porosity of HA
cement paste following implantation, because macropores
are introduced into the HA composite after passive
Figure 8 Compression strength of bone substitutes The compression strength was determined using unconfined compression tests as
described in the Materials and Methods. Each dot represents an individual test sample, and lines indicate the average value. The table below
the figure shows the outcome of the pairwise comparisons (Student’s T-test with Bonferroni correction). *, p < 0.05; **, p < 0.01; ***, p < 0.005;
ns, not statistically significantly different. Grey boxes represent the self-self combinations, which could not be tested.
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resorption of the b-TCP component. Subsequently, active
resorption by monocytes/macrophages and osteoclasts can
take place. Overall, calcium phosphate cement offers the
highest mechanical compressive strength of any of the
osteoconductive bone graft substitutes. Products such as
BoneSource®, Calcibon®, ChronOs® Inject, HydroSet™,
and Norian SRS® are densely packed at first, but will
develop a porous network following resorption of the
b-TCP component. Norian SRS® and BoneSource® have
been studied the most; their clinical indications include
fractures of the femur [60-63], tibia plateau [60,64,65], cal-
caneus [60,66,67], humerus [60,68], and distal radius
[60,69-72]. Calcibon® is mostly used in vertebral augmen-
tation [73-75]. There are currently no publications on the
clinical use of Eurobone®.
Of the available osteoconductive bone graft substi-
tutes, calcium sulphate is the most rapidly resorbed.
Because of its rapid resorption rate and low mechanical
strength, calcium sulphate is recommended as a bone
graft extender rather than as void filler. Clinical indica-
tions of MIIG® X3 include fractures of the distal tibia
and tibia plateau [76,77].
Bioactive glass possesses superior mechanical strength
compared with calcium phosphate products, as a result
of strong graft-bone bonding [1]. It is mainly used in cra-
niofacial reconstructive surgery, dental, and orthopaedic
trauma surgery. Cortoss® is a low-viscosity glass-based
cement that has been used successfully in fractures of the
distal radius [78] and in vertebral augmentation [79,80].
The current study is restricted to biomechanical test-
ing of bone substitute materials in vitro. As a next step,
the biological behavior of these products in vivo should
be determined in a standardized, comparative study.
Pastes may harden less quickly in an aqueous dispersion
in vivo, which may affect it ultimate strength. Combin-
ing data of our previous systematic review [19] with the
Figure 9 Young’s modulus of bone substitutes The Young’s modulus was determined using unconfined compression tests as described in
the Materials and Methods. Each dot represents an individual test sample, and lines indicate the average value. The table below the figure
shows the outcome of the pairwise comparisons (Student’s T-test with Bonferroni correction). *, p < 0.05; **, p < 0.01; ***, p < 0.005; ns, not
statistically significantly different. Grey boxes represent the self-self combinations, which could not be tested.
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data of the current in vitro study and a future in vivo
study will allow for the development of a clinical
guideline.
Conclusions
The nine bone substitutes studied each have their indi-
vidual characteristics, and provide orthopaedic trauma
surgeons with a choice of products that varies largely in
architecture and strength. Only for Eurobone® and Cor-
toss® the pore sizes exceed the 100 μm that is regarded
necessary for proper osteoconduction. Biological and
biomechanical characteristics of bone substitutes deter-
mine their applicability and success rate. Therefore, the
in vivo behavior of these compounds (e.g., resorption
rate and quality in bone ingrowth) should be taken into
account as well. In general, bioactive glass will not
resorb, and HA cements will remain in place for years.
On the other hand, calcium sulphate cements may dis-
appear before bone ingrowth has taken place. Calcium
phosphate cements are generally densely packed and,
consequently, provide more mechanical strength. The
data outlined here will assist surgeons in selecting the
most suitable product for specific clinical indications.
Further studies on their in vivo behavior are needed for
developing clinical guidelines for use of alternative bone
substitute materials in orthopaedic trauma surgery.
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